Evotec AG (EVTCY)
(Delayed Data from OTC)
$50.17 USD
+0.76 (1.54%)
Updated May 1, 2019 10:20 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Evotec AG [EVTCY]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Evotec AG
Industry: Medical - Drugs
Company: Evotec AG
Industry: Medical - Drugs
We are dropping coverage of EVT.GR shares due to the departure of the covering analyst
Provider: Roth Capital Partners, Inc.
Company: Evotec AG
Industry: Medical - Drugs
Impressive 2Q''17, as Integration and Cross-Selling Capture Our Attention
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
Evotec?s Accretive Acquisition of Aptuit Expands Capacity, Adds Mfr?g
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evotec AG
Industry: Medical - Drugs
EVT Innovate Partnerships Now Valued; Raising PT to ?16.00
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evotec AG
Industry: Medical - Drugs
Strong Quarter; 2016 Profitability Guidance Increased
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
Partnered Pipeline Progresses; Endometriosis Candidate Into Ph1
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evotec AG
Industry: Medical - Drugs
Strong Q1 and Strong Fundamentals; Raising PT to ?5.50
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
2015 Meets Targets; From Pipeline to Company, Topas Is Spun-out
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evotec AG
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Evotec AG
Industry: Medical - Drugs
4th Milestone Reached in Bayer''s Endometriosis Program
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
Q3 Results Slightly Short of Expectations, But 2015 Guidance Unchanged
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
Sanofi Integration Underway; 2015 Guidance Unchanged
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
With 1Q15 Results in, Modeling of Sanofi Agreement Develops
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Evotec AG
Industry: Medical - Drugs
We are initiating coverage of Evotec AG with a Buy rating and a ?6.00 price target
Provider: Roth Capital Partners, Inc.
|